NCT06975423 Walking Sensation Study

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2025-09-08 with a primary completion date of 2027-01-31.

Brief Summary

The primary objective of this new line of research is to test whether augmenting sensory information from the legs, using Walkasins sensory neuroprosthesis, can enhance performance of a complex walking task in older adults with foot sensory impairment. The overarching hypothesis is that Walkasins will enhance the automaticity and reduce cognitive demand of walking in older adults with foot sensory impairments, as measured by reduced prefrontal activity, decreased dual-task costs, and lower gait variability.

Eligibility Criteria

Inclusion Criteria: * Not having any significant existing medical conditions, historical health issues, or medications (outlined in the exclusion criteria table above) that could impede the execution of the walking task and assessment. * age 65 - 95. * no severe high blood pressure (systolic \< 180 mmHg and/or diastolic \< 100 mmHg at rest). * no severe vision impairment: visual acuity ≥ 20/70 as determined by Snellen eye chart. * slow walking speed: preferred walking speed slower than 1.0 m/s over 10 meter. * no cognitive impairment: Montreal Cognitive Assessment (MoCA) score ≥ 26 out of 30 possible points. * foot sensory impairment: Inability to feel the 10 g monofilament at ≥1 of 10 tested sites on either foot is considered a sign of impaired protective sensation. loss. Exclusion Criteria: * diagnosed neurological disorder or injury of the central nervous system, or observation of symptoms consistent with such a condition (Alzheimer's, Parkinson's, stroke, etc.) * severe arthritis, such as awaiting joint replacement * current cardiovascular, lung or renal disease; untreated diabetes; terminal illness * myocardial infarction or major heart surgery in the previous year * cancer treatment in the past year, except for nonmelanoma skin cancers and cancers having an excellent prognosis (e.g., early stage breast or prostate cancer) * current diagnosis of schizophrenia, other psychotic disorders, or bipolar disorder * currently taking medications that affect the central nervous system, such as benzodiazepines, anti-cholinergic medication, and GABAergic medication, among others * no severe vision impairment (visual acuity ≥ 20/70 as determined by Snellen eye chart) * uncontrolled hypertension at rest (systolic \> 180 mmHg and/or diastolic \> 100 mmHg) * bone fracture or joint replacement in the previous six months * current enrollment in any other clinical trial * planning to relocate out of the area during the study period * non-English\* speaking, due to the likelihood of difficulties following instructions and communicating remotely * clinical judgment of the investigative team

Contact & Investigator

Frequently Asked Questions

Related Trials